**ARTHRITIS**

**MicroRNA-183 attenuates osteoarthritic pain by inhibiting the TGFα-mediated CCL2/CCR2 signalling axis**

Z. Tao, Y. Zhou, B. Zeng, X. Yang, M. Su

From Central Laboratory of Xiangya Hospital of Central South University, Changsha, China

**Aims**
MicroRNA-183 (miR-183) is known to play important roles in osteoarthritis (OA) pain. The aims of this study were to explore the specific functions of miR-183 in OA pain and to investigate the underlying mechanisms.

**Methods**
Clinical samples were collected from patients with OA, and a mouse model of OA pain was constructed by surgically induced destabilization of the medial meniscus (DMM). Reverse transcription quantitative polymerase chain reaction was employed to measure the expression of miR-183, transforming growth factor α (TGFα), C-C motif chemokine ligand 2 (CCL2), proinflammatory cytokines (interleukin (IL)-6, IL-1β, and tumour necrosis factor-α (TNF-α)), and pain-related factors (transient receptor potential vanilloid subtype-1 (TRPV1), voltage-gated sodium 1.3, 1.7, and 1.8 (Nav1.3, Nav1.7, and Nav1.8)). Expression of miR-183 in the dorsal root ganglia (DRG) of mice was evaluated by in situ hybridization. TGFα, CCL2, and C-C chemokine receptor type 2 (CCR2) levels were examined by immunoblot analysis and interaction between miR-183 and TGFα, determined by luciferase reporter assay. The extent of pain in mice was measured using a behavioural assay, and OA severity assessed by Safranin O and Fast Green staining. Immunofluorescent staining was conducted to examine the infiltration of macrophages in mouse DRG.

**Results**
miR-183 was downregulated in tissue samples from patients and mice with OA. In DMM mice, overexpression of miR-183 inhibited the expression of proinflammatory cytokines (IL-6, IL-1β, TNF-α) and pain-related factors (TRPV1, Nav1.3, Nav1.7, and Nav1.8) in DRG. OA pain was relieved by miR-183-mediated inhibition of macrophage infiltration, and dual luciferase reporter assay demonstrated that miR-183 directly targeted TGFα.

**Conclusion**
Our data demonstrate that miR-183 can ameliorate OA pain by inhibiting the TGFα-CCL2/CCR2 signalling axis, providing an excellent therapeutic target for OA treatment.

Cite this article: Bone Joint Res 2021;10(8):548–557.

**Keywords:** Osteoarthritis pain, microRNA-183, Transforming growth factor α, C-C motif chemokine ligand 2, C-C chemokine receptor 2, Inflammatory factor

**Introduction**
Osteoarthritis (OA) remains one of the most frequently occurring joint abnormalities, and causes an increasing social and economic burden.1 Numerous factors contribute to the development of OA, such as body weight, diet, age, and history of trauma.2,3 Histological examination shows that loss of chondrocytes is a major cause of OA, as chondrocytes are critical for the formation and maintenance of the articular cartilage.4 Pain is the major symptom of OA; however, current treatments for OA are inadequate in terms of therapeutic effect,5,6 making joint arthroplasty surgery the only effective treatment.7 Hence, there is an urgent need to explore the detailed mechanisms underlying OA, to facilitate development of new therapies for OA pain.

MicroRNAs (miRNAs) have critical functions in targeting several leading OA risk factors, such as TGFα and CCL2, which are key mediators of OA pain.8,9 miR-183 is a crucial microRNA that regulates various biological processes and is involved in the development of several diseases including OA.10,11 The expression of miR-183 is downregulated in tissue samples from patients with OA, and its overexpression ameliorates OA pain in animal models.12,13 The aim of this study was to further investigate the specific functions of miR-183 in OA pain and to explore its potential as a therapeutic target for OA.
TGF-α is commonly expressed in diverse tissues and cells. Further, miR-183 can be applied as a powerful therapy to reduce joint pain in a mouse model of OA. Moreover, miR-126 is associated with the development of OA. As a miRNA highly conserved among species, miR-183 is also belongs to the TGF-β family and is closely associated with OA. For example, TGFα expression is increased in rat and human OA cartilage and modifies the phenotype of chondrocytes. Further, TGF-β1 activation is reported to contribute to OA progression, and studies in a murine model of OA revealed the involvement of TGFα. Interestingly, the results of a database search predicted that miR-183 targets TGFα, indicating that miR-183 may influence TGFα activity to regulate the pathogenesis of OA.

C-C motif chemokine ligand 2 (CCL2) is a member of the C-C chemokine family that is related to disease status and outcomes of OA. CCL2 can specifically bind to C-C chemokine receptor type 2 (CCR2), which is expressed in diverse tissues, and both proteins have been associated with OA. For example, inhibition of CCL2/CCR2 signalling significantly inhibits macrophage accumulation, synovitis, and cartilage damage in a mouse OA model. In this study, we investigated the regulatory mechanisms involving miR-183 in OA pain in relation to the TGFα chemokine signalling pathway.

**Methods**

**Ethics statement.** This study was approved by the Ethics Committee and Animal Care and Use committee of our hospital. All participating patients signed informed consent documents. The animal experiments were performed in compliance with the National Institute of Health’s Guidelines of Laboratory Animal Care and Use in Biomedical Research, and the ARRIVE checklist was completed to show that ARRIVE guidelines were adhered to in this study.

**Patient enrolment.** Patients with (n = 95) and without (n = 60) OA recruited in our hospital from January 2012 to December 2016 were enrolled in the study. The 95 patients with OA included 37 males and 58 females (mean age: 58.64 years (standard deviation (SD) 5.32); mean BMI: 25.04 kg/m² (SD 4.07)), among whom 39 were diagnosed with diabetes. Patients who met all the following conditions were included: diagnosis of OA; recurrent knee pain lasting for nearly one month; radiographs indicating joint space narrowing and subchondral abnormalities, such as cysts, sclerosis, or osteophyte formation; appearance of thick and clear synovial fluid with white blood cell count < 2,000/ml; over 40 years of age; and morning stiffness lasting < 30 minutes, with a sensation of ‘grinding’. Patients who met the following conditions were excluded: allergic constitution; pregnant or lactating female; severe abnormalities affecting other organs, such as heart, brain, liver, or kidney; diagnosis of other arthritic diseases, such as rheumatoid arthritis, gouty arthritis, meniscus injury, synovitis, or ligament injury; and medicated with non-steroidal anti-inflammatory drugs (NSAIDs) in the past three months, or cortisol or hyaluronic acid preparations in the past six months. The 60 patients without OA, who served as the control group, included 23 males and 38 females (mean age: 58.72 years (SD 4.0)), had no knee joint deformity or pain in either lower limb, no history of knee joint or surrounding soft tissue injury, and no history of OA, other chronic OA, or knee joint surgery. There were no significant differences in sex or age between the two groups of patients.

**Surgical destabilization of the medial meniscus to generate a mouse OA model.** A total of 105 male wild-type (WT) C57BL/6 mice (mean age: 8 weeks (SD 1)) were housed in a controlled environment with food and water provided ad libitum and maintained under a 12-hour light/dark cycle. An OA mouse model was constructed by destabilization of the medial meniscus (DMM). DMM or sham surgery was performed on the right knees of male mice with a mean age of 8±1 weeks. The dissected anterior medial meniscus ligament was exposed after removal of the medial ankle joint and dissection of the anterior fat pad. The incision was closed after the knee had been washed with saline. Sham surgery was the same as DMM, except that the medial meniscus ligament was left intact.

Adenoviruses carrying miR-183-agonim, miR-183-antagonim, agomir-negative control (NC), antagonim-NC, overexpressed (oe)-TGFα, and oe-NC were purchased from GeneChem (China). Seven days after DMM surgery, mice were anaesthetized with 3% sodium pentobarbital (Cat. No. P3761; MilliporeSigma, USA). Thereafter, adenovirus (1 × 10⁸ pfu/100 μl) from each group was injected via the tail vein, with eight mice in each treatment group. The CCR2 antagonist, RS504393 (Tocris Cookson, UK), was injected intraperitoneally (5 mg/kg), using the solvent dimethyl sulfoxide (DMSO) as a control.

**Behavioural assessment of pain.** Eight weeks after model establishment, weight distribution between surgical and non-surgical side paws was measured using an IITS massometer (CUSABIO Life Sciences, USA). The force of each limb exerted on a transducer plate on the floor over a given period was recorded, to measure the weight distribution placed on the two paws. Each test took over ten seconds to complete and was repeated 12 times. Mean results were expressed as the proportion of weight distribution between the limbs (left and normal vs right and arthritis). Due to the pain caused by OA, the weight on
microRNA-183 (miR-183) expression was reduced in osteoarthritis (OA) tissue samples. a) Quantitative reverse transcription polymerase chain reaction (RT-qPCR) analysis of miR-183 expression in human samples; n = 95 patients; ***p < 0.001 versus the control group. b) Morphological analysis of mouse bone and joint tissue (400×) using Fast Green FCF (0.02%) and Safranin O (0.1%) staining, followed by Osteoarthritis Research Society International (OARSI) scoring; n = 8 mice in each group; ***p < 0.001 versus the sham group. c) Evaluation of pain in mice by behavioural assessment; the weight distribution between paws on the surgical and non-surgical sides was measured using an IITS manometer (“Ratio L/R” refers to the ratio of left and normal to right and arthritis); n = 8 mice in each group; ***p < 0.001 versus the sham group. d) In situ hybridization assay for miR-183 expression in mouse L3-L5 DRG (400×). e) RT-qPCR analysis to evaluate miR-183 expression in mouse L3-L5 DRG; n = 8 mice in each group; experiments were repeated three times; ***p < 0.001 versus the sham group. The above results were all measurement data, and expressed as means (standard deviation (SD)). Independent-samples t-test was used for comparisons between two groups. DMM, destabilization of the medial meniscus.

the knee joint with surgery was less than that without surgery, resulting in a different proportion between the two paws.

**Histomorphometric analysis.** Eight weeks after DMM surgery, mice were euthanized using 3% sodium pentobarbital. The bone and tissue samples were collected and fixed by immersion in 4% paraformaldehyde overnight. Starting the next day, samples were decalcified in 5% methanol for seven days, then embedded in paraffin and cut into 5 μm-thick sections, followed by Fast Green FCF (0.02%) and Safranin O (0.1%) staining. The Osteoarthritis Research Society International (OARSI) scoring system was used to evaluate histopathological changes in the joints.

**In situ hybridization assay.** Mice were euthanized with 3% sodium pentobarbital before extraction of their spines, which were fixed by overnight immersion in 4% formaldehyde. The ipsilateral L3-L5 dorsal root ganglia (DRG) was embedded and cut into 16 μm-thick sections. A mouse-specific miR-183 probe was purchased from Roche (USA). In situ hybridization (ISH) of miR-183 was performed using digoxigenin-labelled riboprobes (Roche), according to the manufacturer’s instructions. After the paraffin sections were deparaffinized and dehydrated, they were digested with proteinase K at 37°C for 30 minutes. After pre-hybridization for one hour, probe-containing hybridization solution was added dropwise to each section at 95°C for five minutes and overnight at 37°C. After washing with hybridization solution, the sections were dripped with mouse anti-digoxigenin biotin-labelled antibody working solution, and incubated in a humid chamber at 37°C for 45 minutes. Then, the sections were dripped with peroxidase streptavidin complex working solution, and incubated for 45 minutes at 37°C. After the 3, 3’-diaminobenzidine (DAB) colouration of the sections, the cytoplasm was observed under an optical microscope. The brown-yellow particles indicated a positive reaction, and the nucleus was blue.

**Immunofluorescence assay.** After the harvested spines were stored in 30% sucrose (Wt/Vol), individual ipsilateral L3-L5 DRG was embedded in optical coherence tomography (OCT) (Tissue-Tek, 4583; Sakura, USA) and frozen, and then cut into 12 μm sections. The sections were incubated with the primary antibodies anti-F4/80 (ab6640) and anti-doublecortin (ab77450; both Abcam, UK), followed by incubation with corresponding isotype-specific secondary antibodies and labelling with either AlexaFluor-488 or AlexaFluor-633 (Invitrogen, Thermo Fisher Scientific, USA). The sections were observed and photographed under a fluorescence microscope. Micrographic images were exported to Adobe Photoshop CS 5.1 (Adobe, USA) and adjusted for brightness and contrast to reflect the true colours. F4/80 positive cells
Overexpression of microRNA-183 (miR-183) ameliorated osteoarthritis (OA) joint pain. a) In situ hybridization assay to evaluate miR-183 expression in mouse L3-L5 dorsal root ganglia (DRG) (400×). b) Quantitative reverse transcription polymerase chain reaction (RT-qPCR) evaluation of miR-183 expression in mouse L3-L5 DRG. c) Evaluation of mouse pain by behavioural assessment; the weight distribution between surgical and non-surgical side paws was measured using an IITS manometer (“Ratio L/R” refers to ratio of left and normal to right and arthritis). d) RT-qPCR evaluation of pro-inflammatory cytokine (tumour necrosis factor α (TNF-α), interleukin (IL)-6, IL-1β) levels in mouse L3-L5 DRG. e) Evaluation of pain-related factors (transient receptor potential vanilloid subtype-1 (TRPV1), voltage-gated sodium 1.3, 1.7, and 1.8 (Nav1.3, Nav1.7, and Nav1.8)) in mouse L3-L5 DRG. f) Immunofluorescent analysis of macrophage infiltration in mouse L3-L5 DRG (400×). g) Morphological analysis of mouse bone and joint tissue (400×) using Fast Green FCF (0.02%) and Safranin O (0.1%) staining, followed by Osteoarthritis Research Society International (OARSI) scoring. **p < 0.01; ***p < 0.001. The results were measurement data, and expressed as means (standard deviation (SD)). Comparisons among multiple groups were analyzed by analysis of variance (ANOVA), followed by Tukey’s post hoc test. n = 8 mice in each group. Experiments were repeated three times. DCX, doublecortin; DMM, destabilization of the medial meniscus; mRNA, messenger RNA; NC, negative control.
showed red fluorescence, doublecortin positive cells showed green fluorescence, and cells expressing both at the same time appeared yellow. **Dual luciferase reporter assay.** Target genes of miR-183 were predicted using the bioinformatics tool, TargetScan. A synthetic WT TGFα three prime untranslated region (3’UTR) fragment was introduced into the pMIR-reporter (Beijing Huayueyang Biological Technology, China). Based on the WT template, mutated (MUT) TGFα 3’UTR was generated and inserted into the empty pMIR-reporter between the same cloning sites. The correctly sequenced luciferase reporter plasmids (WT and MUT, respectively) were cotransfected into HEK293T cells, with miR-183 mimic or NC mimic, respectively. After 48 hours of transfection, cells were collected and lysed, with the luciferase activity measured.

**RNA isolation and quantitation.** Total RNA was extracted from tissue samples and reverse transcribed. Primers (Supplementary Tables i and ii) were synthesized by Invitrogen. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and U6 were used as internal reference genes. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) experiments were performed on an ABI 7500 quantitative PCR machine (Thermo Fisher Scientific) using a SYBR Premix Ex Taq (Tli RNaseH Plus) kit (RR820A; Takara Bio, Japan). Data were analyzed using the 2^ΔΔCt method.

**Western blot analysis.** Proteins were isolated from cells using radioimmunoprecipitation assay buffer and subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After transfer onto polyvinylidene fluoride membranes, samples were blocked with Tris-buffered saline containing Tween 20 (TBST) and 5% bovine serum albumin. Thereafter, membranes were incubated with diluted primary antibodies, as follows: anti-β-actin (ab179467, 1:5,000; Abcam), anti-TGFα (ab92486, 1:500; Abcam), anti-CCL2 (#2029, 1:1,000; Cell Signaling Technology (CST), USA), or anti-CCR2 (ab203128, 1:1,000; Abcam), overnight at 4°C. Subsequently, horseradish peroxidase-conjugated secondary antibody (ab150077, 1:1,000; Abcam) was applied and the membrane was developed using chemiluminescence reagent. Protein levels were quantified using ImageJ software (National Institutes of Health (NIH), USA). Relative standard error (SE) was measured by dividing the densitometry value of the target protein by that of the respective loading control.

**Statistical analysis.** All data were analyzed using SPSS v21.0 software (IBM, USA). Data are expressed as means (SD). Comparisons between paired groups with normally distributed data and homogeneous variances were conducted by paired t-test. Comparison between unpaired groups with adjacent distribution and homogeneous variance was conducted using independent-samples t-test. Comparisons among multiple groups were conducted by one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test. Comparisons among groups at different timepoints were conducted by repeated measures analysis of variance (ANOVA), followed by Bonferroni’s post hoc test. A p-value < 0.001 was regarded as statistically significant.

**Results**

**microRNA-183 downregulation in OA.** RT-qPCR results showed that miR-183 expression was lower in tissue...
microRNA-183 (miR-183) ameliorated osteoarthritis (OA) joint pain by inhibiting TGFα-CCL2/CCR2 signalling. a) Representative immunoblotting images and quantitative analysis of the expression of TGFα, CCL2, and CCR2. b) Evaluation of mouse pain by behavioural assessment; the weight distribution between surgical and non-surgical side paws was measured using an IITS manometer (**Ratio L/R** refers to ratio of left and normal to right arthritis). c) Expression of mouse L3-L5 dorsal root ganglia (DRG) pain-related factors examined by reverse transcription polymerase chain reaction (RT-qPCR). d) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. e) Representative images of immunofluorescence for macrophage infiltration in mouse L3-L5 dorsal root ganglia (DRG). f) Expression of inflammatory factors in L3-L5 DRG examined by RT-qPCR in mice. g) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. h) Representative images of immunofluorescence for macrophage infiltration in mouse L3-L5 dorsal root ganglia (DRG). i) Expression of inflammatory factors in L3-L5 DRG examined by RT-qPCR in mice. j) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. k) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. l) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. m) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. n) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. o) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. p) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. q) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. r) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. s) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. t) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. u) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. v) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. w) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. x) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. y) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice. z) Expression of proinflammatory cytokines in L3-L5 DRG examined by RT-qPCR in mice.

**MICRONRA-183 AMELIORATES OSTEOARTHRITIC PAIN BY INHIBITING THE TGFα-MEDIATED CCL2/CCR2 SIGNALLING AXIS**

The results indicated that miR-183 was poorly expressed in OA.

**MICRONRA-183 AMELIORATES OSTEOARTHRITIC PAIN BY INHIBITING THE TGFα-MEDIATED CCL2/CCR2 SIGNALLING AXIS**

samples from patients with OA than that in those without OA (p < 0.001, independent-samples t-test, Figure 1a). Moreover, histomorphometric analysis (p < 0.001, independent-samples t-test, Figure 1b) revealed significantly reduced cartilage and increased joint pain (p < 0.001, independent-samples t-test, Figure 1c) in DMM mice (p < 0.001). Further, ISH and RT-qPCR assays showed that miR-183 expression was reduced in DRG of DMM mice (p < 0.001, independent-samples t-test, Figures 1d and 1e). These results indicated that miR-183 was poorly expressed in OA.
microRNA-183 (miR-183) inhibited TGFα-CCL2/CCR2 signalling to alleviate the extent of osteoarthritis (OA). Morphological analysis of mouse bone and joint tissues (400×) using Fast Green FCF (0.02%) and Safranin O (0.1%) staining was conducted, followed by Osteoarthritis Research Society International (OARSI) scoring. ***p < 0.001. The results were measurement data, and expressed as means (standard deviation (SD)). Comparisons among multiple groups were analyzed by analysis of variance (ANOVA), followed by Tukey’s post hoc test. n = 8 mice in each group. Experiments were repeated three times. DMSO, dimethyl sulfoxide; NC, negative control; oe, overexpressed; TGFα, transforming growth factor α.

all one-way ANOVA) showed that the inflammatory factors, IL-6, IL-1β, and TNF-α, and the pain-related factors (transient receptor potential vanilloid subtype-1 (TRPV1), voltage-gated sodium 1.3, 1.7, and 1.8 (Nav1.3, Nav1.7, and Nav1.8)) were upregulated in DRG of DMM mice. Notably, this upregulation was inhibited in response to miR-183 overexpression and promoted by miR-183 silencing (p < 0.05). Consistent with these results, immunofluorescence staining showed that increased miR-183 resulted in decreased macrophage infiltration in DRG of DMM mice, whereas silencing of miR-183 led to an increase in macrophage infiltration (Figure 2f). Moreover, the OARSI scoring system and the quantitative results of articular cartilage histomorphology showed that elevated miR-183 reduced the extent of OA, while decreased miR-183 expression led to an increase in the extent of OA (p < 0.001, one-way ANOVA, Figure 2g).

miR-183 inhibited TGFα and CCL2/CCR2 signal. Bioinformatics analysis using TargetScan predicted that miR-183 binds to TGFα (Figure 3a). It has been documented previously that TGFα affects the occurrence of OA in a CCL2-dependent manner. Dual luciferase reporter assay (Figure 3b) showed that the luciferase activity of WT-TGFα was reduced in mice treated with miR-183 mimic relative to those treated with NC mimic (p < 0.001, independent-samples t-test), while the luciferase activity of MUT-TGFα showed no significant difference (p = 0.505, independent-samples t-test), indicating that miR-183 directly targets TGFα. Then, we further detected the expression of TGFα, CCL2, and CCR2 in mice subjected to different treatments. We found that mice overexpressing miR-183-agomir consistently showed significantly reduced expression of TGFα (mRNA expression: p < 0.001, independent-samples t-test; protein expression: p < 0.001, independent-samples t-test), CCL2 (p < 0.001, independent-samples t-test), and CCR2 (p < 0.001, independent-samples t-test), while mice overexpressing miR-183-antagomir expressed increased levels of TGFα (mRNA expression: p < 0.001, t = 15.57; protein expression: p < 0.001, independent-samples t-test), CCL2 (p < 0.001, independent-samples t-test), and CCR2 (p < 0.001, independent-samples t-test) at both the messenger RNA (mRNA) and protein levels (p < 0.05) (Figures 3c and 3d). In agreement with these results in model mice, TGFα, CCL2, and CCR2 mRNA levels in samples from patients with OA were also upregulated (TGFα: p < 0.001; CCL2: p < 0.001; CCR2: p < 0.001, all independent-samples t-test, Figure 3e). Correlation analysis revealed a negative correlation between miR-183 and TGFα expression in OA (Figure 3f).

These results indicated that miR-183 inhibited TGFα, thereby blocking CCL2/CCR2 signalling. miR-183 ameliorated joint pain of OA by inhibiting TGFα-CCL2/CCR2 signalling. Western blot results (TGFα: p < 0.001; CCL2: p < 0.001; CCR2: p < 0.001, all one-way ANOVA, Figure 4a) showed that levels of TGFα, CCL2, and CCR2 were higher in mice injected with agomir-NC + oe-NC, relative to those injected with miR-183-agomir + oe-NC. Compared with mice injected with miR-183-agomir + oe-NC, levels of TGFα, CCL2, and CCR2 were increased in mice injected with miR-183-agomir + oe-TGFα,
miR-183-agonir + oe-TGFα + DMSO, and miR-183-agonir + oe-TGFα + RS504393 (CCR2 agonist).

The pain behavioural assay results (p < 0.001, one-way ANOVA, Figure 4b) showed decreased pain in mice injected with miR-183-agonir + oe-NC relative to those injected with agomir-NC + oe-NC. The pain of the mice injected with miR-183-agonir + oe-TGFα was increased relative to that in mice injected with miR-183-agonir + oe-NC. The mice injected with miR-183-agonir + oe-TGFα + RS504393 (CCR2 agonist) exhibited significantly lower pain than those injected with miR-183-agonir + oe-TGFα + DMSO.

We also observed decreased proinflammatory cytokines (IL-6, IL-1β, and TNF-α) and pain-related factors (TRPV1, Nav1.3, Nav1.7, and Nav1.8) in DRG from mice injected with miR-183-agonir + oe-NC compared with control littermates (mice injected with agomir-NC + oe-NC) (p < 0.05) (TRPV1: p < 0.001; Nav1.3: p < 0.001; Nav1.7: p < 0.001; Nav1.8: p < 0.001, Figures 4c and 4d; TNF-α: p < 0.001; IL-6: p < 0.001; IL-1β: p < 0.001, all one-way ANOVA). In contrast, overexpression of TGFα neutralized the effect of miR-183 on mediating decreased proinflammatory cytokine levels and pain-related factors (Figures 4c and 4d), indicating that miR-183 downregulates those cytokines and pain-related factors in a TGFα-dependent manner. Interestingly, further blocking CCR2 using the CCR2 agonist, RS504393, also attenuated the effect of TGFα (Figures 4c and 4d). Taken together, these data indicate that miR-183 regulates TGFα, thereby exerting a regulatory effect on the CCL2/CCR2 axis.

Accumulating evidence supports the function of CCL2 as a chemoattractant important in macrophage regulation.22 Therefore, we evaluated macrophage infiltration in mouse DRG by immunofluorescent staining. In the miR-183-agonir + oe-NC group, infiltration was reduced compared with that in the agomir-NC + oe-NC group. Furthermore, macrophage infiltration in the miR-183-agonir + oe-TGFα + RS504393 (CCR2 agonist) group was significantly decreased relative to that in the miR-183-agonir + oe-TGFα + DMSO group (Figure 4e). These data further demonstrate that miR-183 attenuates OA joint pain by regulating the TGFα-CCL2/CCR2 signalling axis.

**miR-183 alleviated the progression of OA by inhibiting TGFα-CCL2/CCR2 signalling.** Evaluation using the OARSI scoring system and articular cartilage histomorphometric analysis demonstrated that the degree of inflammation and bone sclerosis in mice injected with miR-183-agonir + oe-NC was reduced compared with those injected with agomir-NC + oe-NC. Compared with the mice injected with miR-183-agonir + oe-NC, the degree of OA and osteosclerosis was exaggerated in those injected with miR-183-agonir + oe-TGFα (p < 0.001, one-way ANOVA). Moreover, this effect was reversed by additional injection of the CCR2 agonist, RS504393 (Figure 5). In summary, miR-183 can alleviate OA progression by inhibiting the TGFα-CCL2/CCR2 signalling axis.

**Discussion**

OA is the most frequently occurring inflammatory joint disease, and causes pain and impaired mobility in people across the globe,21 affecting approximately 240 million individuals;22 however, early diagnosis of OA is not currently feasible,23 and available treatments for OA are not fully effective and usually have side effects.24 Pain is the major symptom of OA, and NSAIDs are the most common treatment option; however, NSAIDs cannot completely relieve the pain of OA and long-term use of NSAIDs is associated with health risks.27 The origin and mechanisms underlying OA joint pain remain unclear.28 In this study, we found that miR-183 could ameliorate OA pain through inhibiting the TGFα-CCL2/CCR2 signalling axis.

Our initial results showed that miR-183 expression was reduced in joint tissue from patients with OA and murine OA models. Furthermore, miR-183 overexpression inhibited the production of proinflammatory cytokines, such as IL-6, IL-1β, and TNFα. Simultaneously, pain-related factors, including TRPV1, Nav1.3, Nav1.7, and Nav1.8, were also downregulated. IL-6 has a vital role in mediating inflammation and consequent metabolic changes,29 while IL-1β is a pro-inflammatory factor and a therapeutic target in some chronic autoimmune conditions.30 In contrast, TGFα and TGF-β1 are mainly known as anti-inflammatory factors.31 Transient receptor potential ankyrin 1 (TRPA1) is generally considered to be a pain receptor in sensory neurones, and inhibition of TRPV1 is reported to participate in the inhibitory effect of the TRPA1 ion channel on T cell-mediated colitis.32 Concerning pain-related factors, increased expression of certain Nav isoforms in peripheral sensory neurones is related to chronic and neuropathic pain conditions.33 Consistent with our findings, targeting the miR-183 cluster can treat OA and alleviate joint pain.12 The miR-183 cluster can regulate basal and neuropathic pain genes to rescale mechanical pain sensitivity.34 Macrophages are critical players in the innate immune system, and constitute the first line of defence against pathogen invasion and in regulating adaptive immunity.35 Moreover, macrophages are important in OA pathology.36 In this study, we found that miR-183 inhibited macrophage infiltration in affected joints. OA is caused by destruction of osteoclast formation and function.37 The results of this study revealed that miR-183 ameliorated OA.

Further, we found that miR-183 overexpression inhibited TGFα expression, thereby downregulating CCL2/CCR2 signalling. Consistent with our findings, TGFα levels were increased in OA cartilage from rats and humans.15 Furthermore, CCL2 and CCR2 are crucial to the development of pain associated with knee OA.38 CCL2 expression is higher in articular cartilage samples from patients with OA compared with controls.39 and CCR2+ cells are abundant in human OA synovium.29 TGFα is documented as a major factor involved in inducing OA pain,40 while CCL2/CCR2 signalling is an important trigger in the progression of pain in murine OA.41 TGFα induces
cartilage degradation by a CCL2-dependent mechanism in experimental post-traumatic OA.\(^{13}\) In this experiment, TGFrα, CCL2, and CCR2 expression levels were inhibited by miR-183 overexpression, and together alleviated OA pain. Further, through inhibiting the expression of TGFrα, CCL2, and CCR2, miR-183 ameliorated the extent of OA.

In conclusion, based on these findings, we propose that miR-183 inhibits the expression of TGFrα and consequently suppresses CCL2/CCR2 signalling to alleviate OA pain (Supplementary Figure a), thus providing a promising therapeutic target for OA. However, additional works should be performed to warrant further exploration in the clinical setting.

**Supplementary material**

Figure depicting the mechanism of this study. Tables showing primer sequences for human quantitative reverse transcription polymerase chain reaction (RT-qPCR) and mouse primer sequences for RT-qPCR. ARRIVE checklist also included.

**References**

1. Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072.
2. Einer A, Pester J, Vogel F, et al. Pain sensation in human osteoarthritic knee joints is strongly enhanced by diabetes mellitus. Pain. 2017;158(9):1743–1753.
3. Collins KH, Hart DA, Seerattaran RA, Reimer RA, Herzog W. High-fat/high-sucrose diet-induced obesity results in joint-specific development of osteoarthritis-like degeneration in a rat model. Bone Joint Res. 2018;7(4):274–281.
4. Hosseinazadeh A, Kamrava SK, Joghataei MT, et al. Apoptosis signaling pathways in osteoarthritis and possible protective role of melatonin. J Pineal Res. 2016;61(4):411–425.
5. Perrot S. Osteoarthritis pain. Best Pract Res Clin Rheumatol. 2015;29(1):90–97.
6. Walsh DA, Stocks J. New therapeutic targets for osteoarthritis pain. SLAS Discov. 2017;22(8):491–549.
7. Sacittaran PK. Ageing and osteoarthritis. Subcell Biochem. 2019;91:123–159.
8. Hu J, Wang Z, Pan Y, et al. Mir-26a and mir-26b mediate osteoarthritis progression by targeting FUT4 via NF-κB signaling pathway. Int J Biochem Cell Biol. 2018;94:79–88.
9. Wang H, Zhang H, Sun Q, et al. Intra-articular Delivery of Antago-miR-483-5p Inhibits Osteoarthritis by Modulating Matrilin 3 and Tissue Inhibitor of Metalloproteinase 2. Mol Ther. 2017;25(3):715–727.
10. Yu CD, Miao WH, Zhang YY, Zou MJ, Yan XF. Inhibition of miR-126 protects chondrocytes from IL-1β induced inflammation via upregulation of Bel-2. Bone Joint Res. 2018;7(6):414–421.
11. Zhao W, Yang H, Li J, et al. Mir-183 promotes preadipocyte differentiation by suppressing Smad2 in mice. Gene. 2019;666:158–164.
12. Wu O, Gardiner GJ, Berry E, et al. ICD5-expressing lymphocytes promote resolution of CDB-mediated lung injury in a mouse model of lung rejection. PLoS One. 2013;8:e72955.
13. Li J, Fu H, Xu C, et al. miR-183 inhibits TGFBeta1-induced apoptosis by downregulation of FODCD4 expression in human hepatocellular carcinoma cells. BMC Cancer. 2010;10:394.
14. Nickel J, Ten Dijke P, Mueller TD. TGFB family co-receptor function and signaling. Acta Biochim Biophys Sin. 2016;48(1):12–36.
15. Appleton CTG, Usmani SE, Pest MA, et al. Reduction in disease progression by inhibition of transforming growth factor α/CC2L signaling in experimental posttraumatic osteoarthritis. Arthritis Rheumatol. 2015;67(10):2981–2701.
16. Zhang R-K, Li G-W, Zeng C, et al. Mechanical stress contributes to osteoarthritis development through the activation of transforming growth factor beta 1 (TGFB1). Bone Joint Res. 2018;7(11):587–594.
17. Usmani SE, Appleton CTG, Beier F. Transforming growth factor-alpha induces endothelin receptor A expression in osteoarthritis. J Orthop Res. 2012;30(9):1391–1397.
18. Lin Y-M, Hsu C-J, Liao Y-J, Chou M-C, Tang C-H. The CCL2/CCR2 axis enhances vascular cell adhesion molecule-1 expression in human synovial fibroblasts. PLoS One. 2012;7(11):e49899.
19. Zhuang H, Cao G, Kou C, Liu T. CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition in vitro through activation of the Hedgehog pathway. Oncol Rep. 2018;39(1):21–30.
20. Raghu H, Lepus CM, Wang Q, et al. CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. Ann Rheum Dis. 2017;76(5):914–922.
21. No authors listed. TargetScan Release 7.2. Whitehead Institute for Biomedical Research R. 2018. http://www.targetscan.org/vert_72/ (date last accessed 12 January 2021).
22. Yang F, Liu D-Y, Guo J-T, et al. Circular RNA circ-RLAD3 as a biomarker in diagnosis of pancreatic cancer. World J Gastroenterol. 2017;23(47):8345–8354.
23. Guan VY, Mobasheri A, Probst YC. A systematic review of osteoarthritis prevention and management with dietary phytochemicals from foods. Maturitas. 2019;122:35–43.
24. Carlson AK, Rawle RA, Adams E, et al. Application of global metabolomic profiling of synovial fluid for osteoarthritis biomarkers. Biochim Biophys Acta. 2018;18:492(2):182–188.
25. Morales-Ivorra I, Romero-Baures M, Roman-Viñas B, Serra-Majem L. Osteoarthritis and the Mediterranean diet: a systematic review. Nutritions. 2018;10(8):1030.
26. Oo WM, Yu SP-C, Daniel MS, Hunter DJ. Disease-Modifying drugs in osteoarthritis: current understanding and future therapeutics. Expert Opin Emerg Drugs. 2018;23(4):331–347.
27. Malfait A-M, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 2013;9(11):654–664.
28. Zhu S, Zhu J, Zhen G, et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J Clin Invest. 2019;129(3):1076–1099.
29. Kraakman MJ, Kammouln HL, Allen TL, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015;21(3):403–416.
30. Asgari E, Le Friec G, Yamamoto H, et al. C3A modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. 2013;122(20):3473–3481.
31. Brianna DD, Liossi S, Gourgiotis D, et al. Fetal concentrations of the growth factors TGF-α and TGF-β1 in relation to normal and restricted fetal growth at term. Cytokine. 2012;60(1):157–161.
32. Bertin S, Aoki-Nonaka Y, Lee J, et al. The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1. Gut. 2017;66(9):1584–1596.
33. Hoehne A, Behera D, Parsons WH, et al. A 198-labeled saxitoxin derivative for in vivo PET/MRI imaging of voltage-gated sodium channel expression following neuror injury. J Am Chem Soc. 2013;135(48):18012–18015.
34. Peng C, Li L, Zhang M-D, et al. miR-183 cluster scales mechanical pain sensitivity by regulating basal and neuropathic pain genes. Science. 2017;356(6343): 1168–1171.
35. Muraeedharaman CK, McClellan SA, Ekanayaka SA, et al. The mir-183/96/182 Cluster Regulates Macrophage Functions in Response to Pseudomonas aeruginosa. J Innate Immun. 2019;11(4):347–358.
36. Yang X, Chordia MD, Du X, et al. Targeting formyl peptide receptor 1 of activated macrophages to monitor inflammation of experimental osteoarthritis in rat. J Orthop Res. 2016;34(9):1529–1538.
37. Sobacchi C, Schuel A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9:522–536.
38. Miller RE, Tran PB, Das R, et al. Ccr2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci U S A. 2012;109(50): 20602–20607.
39. Wei M, Xie Q, Zhu J, et al. MicroRNA-33 suppresses CCL2 expression in chondrocytes. Biores Rep. 2016;13(2):e00332.
40. Ohtori S, Ito H, Yamauchi K, et al. Efficacy of direct injection of etanercept into knee joints for pain in moderate and severe knee osteoarthritis. Osteoarthritis Cartilage. 2017;25(3):406–412.
MICRORNA-183 ATTENUATES OSTEOARTHRITIC PAIN BY INHIBITING THE TGF-\(\alpha\)-MEDIATED CCL2/CCR2 SIGNALLING AXIS

Author information:
- Z. Tao, MB, Deputy Director
- Y. Zhou, MD, Deputy Director
- B. Zeng, MM, Head Nurse
- M. Su, MM, Nurse
  Teaching and Research Section of Clinical Nursing, Xiangya Hospital of Central South University, Changsha, China.
- X. Yang, MD, Physician, Department of Orthopedics, Xiangya Hospital of Central South University, Changsha, China.

Author contributions:
- Z. Tao: Conceptualization, Supervision.
- Y. Zhou: Conceptualization, Data curation.
- B. Zeng: Formal analysis, Methodology.
- X. Yang: Visualization, Writing – original draft.
- M. Su: Writing – original draft, Writing – review & editing.

Funding statement:
- This study was supported by the Key research and development projects of Hunan Province (No. 2020SK2075). No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

Open access funding:
- Open access funding was provided by the Key research and development projects of Hunan Province (No. 2020SK2075).

Acknowledgements:
- Not applicable.

Ethical review statement:
- This study was approved by the Ethics Committee and Animal Care and Use committee of our hospital. All participating patients signed informed consent documents. The animal experiments were performed in compliance with the National Institute of Health’s Guidelines of Laboratory Animal Care and Use in Biomedical Research, and the ARRIVE checklist was completed to show that ARRIVE guidelines were adhered to in this study.

© 2021 Author(s) et al. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND 4.0) licence, which permits the copying and redistribution of the work only, and provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc-nd/4.0/.